metformin has been researched along with Leucocythaemia in 9 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effect of metformin on leukemia risk remains unknown." | 7.96 | Metformin Use and Leukemia Risk in Patients With Type 2 Diabetes Mellitus. ( Tseng, CH, 2020) |
| "To investigate the effect of metformin on 3T3-L1 preadipocyte's differentiation and consequently observe the anti-proliferative effects of metformin-treated adipocytes on leukemia cells." | 7.81 | [Metformin Influences the Effect of Adipocytes on Leukemia Cell Chemoresistance through Regulation of Adipogenesis]. ( Liu, SH; Lu, W; Shi, J; Wan, Y; Wang, H; Zhai, YM; Zhu, XY, 2015) |
| "Metformin is an anti-diabetic drug known to have anticancer activity by inhibiting mechanistic target of rapamycin (mTOR); however, other molecular mechanisms may also be involved." | 5.56 | Metformin suppresses the growth of leukemia cells partly through downregulation of AXL receptor tyrosine kinase. ( Itoh, M; Saito, T; Tohda, S, 2020) |
| "The effect of metformin on leukemia risk remains unknown." | 3.96 | Metformin Use and Leukemia Risk in Patients With Type 2 Diabetes Mellitus. ( Tseng, CH, 2020) |
| "To investigate the effect of metformin on 3T3-L1 preadipocyte's differentiation and consequently observe the anti-proliferative effects of metformin-treated adipocytes on leukemia cells." | 3.81 | [Metformin Influences the Effect of Adipocytes on Leukemia Cell Chemoresistance through Regulation of Adipogenesis]. ( Liu, SH; Lu, W; Shi, J; Wan, Y; Wang, H; Zhai, YM; Zhu, XY, 2015) |
| "Metformin is an anti-diabetic drug known to have anticancer activity by inhibiting mechanistic target of rapamycin (mTOR); however, other molecular mechanisms may also be involved." | 1.56 | Metformin suppresses the growth of leukemia cells partly through downregulation of AXL receptor tyrosine kinase. ( Itoh, M; Saito, T; Tohda, S, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (77.78) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Saito, T | 1 |
| Itoh, M | 1 |
| Tohda, S | 1 |
| Tseng, CH | 1 |
| Ravera, S | 1 |
| Cossu, V | 1 |
| Tappino, B | 1 |
| Nicchia, E | 1 |
| Dufour, C | 1 |
| Cavani, S | 1 |
| Sciutto, A | 1 |
| Bolognesi, C | 1 |
| Columbaro, M | 1 |
| Degan, P | 1 |
| Cappelli, E | 1 |
| Cunha Júnior, AD | 1 |
| Pericole, FV | 1 |
| Carvalheira, JBC | 1 |
| Scotland, S | 1 |
| Saland, E | 1 |
| Skuli, N | 1 |
| de Toni, F | 1 |
| Boutzen, H | 1 |
| Micklow, E | 1 |
| Sénégas, I | 1 |
| Peyraud, R | 1 |
| Peyriga, L | 1 |
| Théodoro, F | 1 |
| Dumon, E | 1 |
| Martineau, Y | 1 |
| Danet-Desnoyers, G | 1 |
| Bono, F | 1 |
| Rocher, C | 1 |
| Levade, T | 1 |
| Manenti, S | 1 |
| Junot, C | 1 |
| Portais, JC | 1 |
| Alet, N | 1 |
| Récher, C | 1 |
| Selak, MA | 1 |
| Carroll, M | 1 |
| Sarry, JE | 1 |
| Rosilio, C | 1 |
| Ben-Sahra, I | 1 |
| Bost, F | 1 |
| Peyron, JF | 1 |
| Zhang, B | 1 |
| Liu, LL | 1 |
| Mao, X | 1 |
| Zhang, DH | 1 |
| Wang, H | 1 |
| Liu, SH | 1 |
| Zhai, YM | 1 |
| Zhu, XY | 1 |
| Wan, Y | 1 |
| Lu, W | 1 |
| Shi, J | 1 |
| Vakana, E | 1 |
| Platanias, LC | 1 |
3 reviews available for metformin and Leucocythaemia
| Article | Year |
|---|---|
Metformin and blood cancers.
Topics: Body Mass Index; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Leukemia; Lymphoma | 2018 |
Metformin: a metabolic disruptor and anti-diabetic drug to target human leukemia.
Topics: Animals; Antineoplastic Agents; Humans; Hypoglycemic Agents; Leukemia; Metformin | 2014 |
AMPK in BCR-ABL expressing leukemias. Regulatory effects and therapeutic implications.
Topics: AMP-Activated Protein Kinase Kinases; Genes, abl; Hematologic Neoplasms; Humans; Leukemia; Metformin | 2011 |
6 other studies available for metformin and Leucocythaemia
| Article | Year |
|---|---|
Metformin suppresses the growth of leukemia cells partly through downregulation of AXL receptor tyrosine kinase.
Topics: Axl Receptor Tyrosine Kinase; Down-Regulation; Gene Expression Regulation, Enzymologic; Gene Express | 2020 |
Metformin Use and Leukemia Risk in Patients With Type 2 Diabetes Mellitus.
Topics: Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Leukemia; Male; Metformin; Middle Ag | 2020 |
Concentration-dependent metabolic effects of metformin in healthy and Fanconi anemia lymphoblast cells.
Topics: AMP-Activated Protein Kinases; Case-Control Studies; Cell Survival; DNA Damage; Dose-Response Relati | 2018 |
Mitochondrial energetic and AKT status mediate metabolic effects and apoptosis of metformin in human leukemic cells.
Topics: Adenosine Triphosphate; AMP-Activated Protein Kinases; Animals; Apoptosis; Blotting, Western; Cell P | 2013 |
Effects of metformin on FOXM1 expression and on the biological behavior of acute leukemia cell lines.
Topics: Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neopla | 2014 |
[Metformin Influences the Effect of Adipocytes on Leukemia Cell Chemoresistance through Regulation of Adipogenesis].
Topics: 3T3-L1 Cells; Adipocytes; Adipogenesis; Animals; CCAAT-Enhancer-Binding Protein-alpha; Cell Differen | 2015 |